Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Traumatic Brain Injury
Successful Completion of Phase II Head Trauma Clinical Studies Announced
March 31st, 2000
Pharmos Corp., Iselin, New Jersey, announced the successful completion of the third cohort of its Phase II escalating-dose clinical trial of dexanabinol for traumatic brain injury (TBI). The Phase II goals of establishing the safety of dexanabinol in TBI and the dosing parameters for a pivotal study were met, allowing for the commencement of an international pivotal trial of several hundred patients later in 2000. "The results confirm previous findings that dexanabinol is safe and prevents the elevation of intracranial pressure (ICP) in severe head trauma patients," said Dr. Nachshon Knoller, principle investigator of the study. ...
Source: Drug Week (2000-03-31)
|
